TEST:

SeekInCure®

This prospective study highlights the prognostic value of ctDNA-based tumor-naïve MRD detection through a multi-omics assay in early-stage liver cancer patients.

"SeekIn Inc...announced today that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare (the first-in-class blood-based pan-cancer early detection test), SeekInCure (the first-in-class blood-based pan-cancer recurrence monitoring test), SeekInClarity (pan-cancer treatment response monitoring), OncoSeek (low-cost early cancer detection test), LungCanSeek (lung cancer early detection test), LeukoPrint (the first-in-class leukemia sWGS CNA test), PanCanSeek (pan-cancer therapy guidance test)..."

This prospective study demonstrated the potential clinical value of ctDNA in detecting MRD status to predict the prognosis in early-stage liver cancer patients and to identify patients who may benefit from avoiding overtreatment. This strategy requires validation in independent prospective studies.

"SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."

This study confirms the excellent performance of our SeekInCure assay, which does not require cancer tissue analysis, in detecting MRD and the prognostic value of MRD in HCC patients. Adjuvant has no influence on survival, especially in MRD- patients, which indicates that amost one-third of HCC patients do not need additional adjuvant therapy.

"SeekIn Inc...today announced CE (Conformité Européenne) Mark approval for SeekInCure Cancer Recurrence Monitoring Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark."